UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

SCHEDULE 13G

UNDER THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No.)*

MediWound Ltd.
(Name of Issuer)

Ordinary shares, par value NIS 0.07 per share (Title of Class of Securities)

M68830112

(CUSIP Number)
September 26, 2024 (Date of Event Which Requires Filing of this Statement)
Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
□ Rule 13d-1(b)
⊠ Rule 13d-1(c)
□ Rule 13d-1(d)
* The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.
The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

CUSIP No. M68830112				1	13G	Page 2 of 9 Pages			
1	NAME OF REPORTING PERSONS Dov Yelin								
2	CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (See instructions) (a) (b) (c)								
3	SEC USE ONLY								
4	CITIZENSHIP OR PLACE OF ORGANIZATION Israel								
NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH		5	SOLE VOT	ING POWER					
		6	SHARED V 750,743 (*)	OTING POWER					
		7	SOLE DISF	POSITIVE POWER					
		8 SHARED DISPOSITIVE POWER 750,743 (*)							
9	AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 750,743 (*)								
10	CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (See instructions) □								
11	PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9 6.96% (*) (**)								
12	TYPE OF REP	ORTING :	PERSON (See	instructions)					
	IN								

^(*) The beneficial ownership of the securities reported herein is described in Item 4(a).

^(**) Based on 10,786,423 Ordinary Shares outstanding as of September 27, 2024 (as reported on Bloomberg LP).

CUSIP No. M68830112				13G	Page 3 of 9 Pages					
1	NAME OF REPORTING PERSONS									
	Yair Lapidot									
2	CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (See instructions)									
	(a) □ (b) □									
3	SEC USE ONLY									
4	CITIZENSHIP OR PLACE OF ORGANIZATION									
	Israel									
		5	SOLE VO	TING POWER						
NUMBER OF		6	SHARED '	VOTING POWER						
	HARES EFICIALLY									
	NED BY		750,743 (*							
EACH REPORTING PERSON WITH		7	SOLE DIS	POSITIVE POWER						
		8	SHARED	DISPOSITIVE POWER						
			750,743 (*							
9	AGGREGATE	AMOUN	T BENEFICL	ALLY OWNED BY EACH REPORTING PERSON	1					
	750,743 (*)									
10	CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (See instructions)									
11	PERCENT OF	CLASS R	REPRESENTE	ED BY AMOUNT IN ROW 9						
	6.96% (*) (**)									
12	TYPE OF REP	ORTING	PERSON (Se	e instructions)						
	IN									

^(*) The beneficial ownership of the securities reported herein is described in Item 4(a).

^(**) Based on 10,786,423 Ordinary Shares outstanding as of September 27, 2024 (as reported on Bloomberg LP).

CUSIP No. M68830112				13G	Page 4 of 9 Pages					
1	NAME OF REPORTING PERSONS									
	Yelin Lapidot Holdings Management Ltd.									
2	CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (See instructions)									
	(a) □ (b) □									
3	SEC USE ONLY									
4	CITIZENSHIP OR PLACE OF ORGANIZATION									
	Israel									
		5	SOLE VO	TING POWER						
	MBER OF HARES 6 SHARED VOTING POWER									
BENE	EFICIALLY		750,743 (*))						
OWNED BY EACH REPORTING PERSON WITH		7	SOLE DIS	POSITIVE POWER						
		8	SHARED	DISPOSITIVE POWER						
			750,743 (*))						
9										
	750,743 (*)									
10	CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (See instructions)									
11	PERCENT OF	CLASS R	EPRESENTE	ED BY AMOUNT IN ROW 9						
	6.96% (*) (**)									
12	TYPE OF REP	ORTING	PERSON (Se	e instructions)						
	СО									
(*) TL - 1	£-i-1	.l.i£41		and have in its described in Item 4(a)						

^(*) The beneficial ownership of the securities reported herein is described in Item 4(a).

^(**) Based on 10,786,423 Ordinary Shares outstanding as of September 27, 2024 (as reported on Bloomberg LP)

Item 1. (a)	Name of Issuer:
	MediWound Ltd.
(b)	Address of Issuer's Principal Executive Offices:
	42 Hayarkon Street, Yavne 8122745, Israel
Item 2. (a)	Name of Person Filing:
	Dov Yelin
	Yair Lapidot
	Yelin Lapidot Holdings Management Ltd.
(b)	Address of Principal Business Office:
	Dov Yelin – 50 Dizengoff St., Dizengoff Center, Gate 3, Top Tower, 13th floor, Tel Aviv 64332, Israel
	Yair Lapidot - 50 Dizengoff St., Dizengoff Center, Gate 3, Top Tower, 13th floor, Tel Aviv 64332, Israel
	Yelin Lapidot Holdings Management Ltd. – 50 Dizengoff St., Dizengoff Center, Gate 3, Top Tower, 13th floor, Tel Aviv 64332, Israel
(c)	Citizenship or Place of Incorporation:
	Dov Yelin – Israel
	Yair Lapidot – Israel
	Yelin Lapidot Holdings Management Ltd. – Israel
(d)	Title of Class of Securities:
	Ordinary shares, par value NIS 0.07 per share
(e)	CUSIP Number:
	M68830112
Item 3.	Not applicable.
	5

Item 4. Ownership:

(a) Amount beneficially owned:

See row 9 of cover page of each reporting person.

On September 26, 2024, the securities reported herein were beneficially owned as follows:

- 522,645 Ordinary Shares (representing 4.84% of the total Ordinary Shares outstanding) beneficially owned by provident funds managed by Yelin Lapidot Provident Funds Management Ltd.
- 228,098 Ordinary Shares (representing 2.11% of the total Ordinary Shares outstanding) beneficially owned by mutual funds managed by Yelin Lapidot Mutual Funds Management Ltd.

The securities reported herein are beneficially owned by provident funds managed by Yelin Lapidot Provident Funds Management Ltd. and/or mutual funds managed by Yelin Lapidot Mutual Funds Management Ltd. (the "Subsidiaries"), each a wholly-owned subsidiary of Yelin Lapidot Holdings Management Ltd. ("Yelin Lapidot Holdings"). Mr. Yelin owns 24.38% of the share capital and 25.00% of the voting rights of Yelin Lapidot Holdings, Mr. Lapidot owns 24.62% of the share capital and 25.00% of the voting rights of Yelin Lapidot Holdings. Messrs Yelin and Lapidot are responsible for the day-to-day management of Yelin Lapidot Holdings. In accordance with the Shareholders' Agreement, dated December 5, 2018, until the End of the "Suspension Period" Messrs Yelin and Lapidot are entitled to jointly appoint the majority of the members of Yelin Lapidot Holdings board. The Subsidiaries operate under independent management and make their own independent voting and investment decisions. Any economic interest or beneficial ownership in any of the securities covered by this report is held for the benefit of the members of the provident funds or mutual funds, as the case may be. This Statement shall not be construed as an admission by Messrs. Yelin and Lapidot, Yelin Lapidot Holdings or the Subsidiaries that he or it is the beneficial owner of any of the securities covered by this Statement, and each of Messrs. Yelin and Lapidot, Yelin Lapidot Holdings, and the Subsidiaries disclaims beneficial ownership of any such securities.

(b) <u>Percent of class</u>:

See row 11 of cover page of each reporting person

- (c) Number of shares as to which such person has:
 - (i) Sole power to vote or to direct the vote:

See row 5 of cover page of each reporting person

(ii) Shared power to vote or to direct the vote:

See row 6 of cover page of each reporting person and note in Item 4(a) above

(iii) Sole power to dispose or to direct the disposition of:

See row 7 of cover page of each reporting person

(iv) Shared power to dispose or to direct the disposition of:

See row 8 of cover page of each reporting person and note in Item 4(a) above

Item 5. Ownership of Five Percent or Less of a Class:

Not applicable.

Item 6. Ownership of More than Five Percent on Behalf of Another:

Not applicable.

Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or

Control Person:

Not applicable.

Item 8. <u>Identification and Classification of Members of the Group:</u>

Not applicable.

Item 9. <u>Notice of Dissolution of Group:</u>

Not applicable.

Item 10. <u>Certification</u>:

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.

SIGNATURE

	After reasonable inquiry and to the	best of my knowledge	e and belief, I certify	that the information	set forth in this state	ement is true, o	complete and
correct.							

October 1, 2024

Dov Yelin

/s/ Dov Yelin

By: Dov Yelin

Yair Lapidot

/s/ Yair Lapidot

By: Yair Lapidot

Yelin Lapidot Holdings Management Ltd.

/s/ Dov Yelin

By: Dov Yelin

Title: Joint Chief Executive Officer

EXHIBIT NO. DESCRIPTION

Exhibit 1 Joint Filing Agreement filed by and among the Reporting Persons, dated as of October 1, 2024.

Joint Filing Agreement

Pursuant to Rule 13d-1(k)(1) under the Securities Exchange Act of 1934, as amended, the undersigned hereby agree that only one statement containing the information required by Schedule 13G need be filed with respect to the ownership by each of the undersigned of shares of Mediwound Ltd. Each of them is responsible for the timely filing of such Schedule 13G and any amendments thereto, and for the completeness and accuracy of the information concerning such person contained therein; but none of them is responsible for the completeness or accuracy of the information concerning the other persons making the filing, unless such person knows or has reason to believe that such information is inaccurate. In accordance with Rule 13d-1(k)(1), the undersigned hereby agree to the joint filing with each other on behalf of each of them of such a statement on Schedule 13G and any amendments thereto with respect to the equity securities (as defined in Rule 13d-1(i)) of the issuer, beneficially owned by each of them. This Joint Filing Agreement shall be included as an exhibit to such Schedule 13G and any amendments thereto.

This agreement may be executed in any number of counterparts, each of which shall be deemed an original.

October 1, 2024

Dov Yelin

/s/ Dov Yelin

By: Dov Yelin

Yair Lapidot

/s/ Yair Lapidot

By: Yair Lapidot

Yelin Lapidot Holdings Management Ltd.

/s/ Dov Yelin

By: Dov Yelin

Title: Joint Chief Executive Officer